@genetic-counselor
Genetic Counselor
Forum Replies Created
-
Posts
-
An inconclusive result means the test wasn’t able to give a clear answer, either because no gene change was found even though the condition is still suspected, or because the finding couldn’t be clearly linked to your symptoms. Your geneticist may recommend a different test, testing other family members, or revisiting the case in the future as testing technology improves.
Yes. As research grows and more data becomes available, a variant initially labeled uncertain may later be reclassified as either disease-causing or harmless. Some clinics offer to re-contact patients if a reclassification affects their result.
A normal result reduces the risk for the specific conditions or genes tested, but no test can rule out every possible health condition. It’s best understood as ruling out particular known risks, not a complete guarantee of health.
Yes, it can still be worthwhile. Many people are carriers of recessive conditions without any family history, since carriers themselves show no symptoms. General carrier screening can uncover risks that a family history alone wouldn’t reveal.
Causes are generally grouped into three categories: placental, maternal, and fetal. Placental causes, such as poor placental implantation or insufficiency, account for the majority of cases. Maternal causes include chronic hypertension, pre-eclampsia, diabetes with vascular disease, autoimmune conditions, smoking, and undernutrition. Fetal causes include chromosomal abnormalities, structural anomalies, congenital infections, and genetic syndromes. Genetic testing becomes particularly relevant when growth restriction is early-onset (before 32 weeks), severe, symmetric (affecting both head and body proportionately), or accompanied by structural anomalies on ultrasound. In such cases, chromosomal microarray analysis is generally recommended over standard karyotyping alone, as it detects smaller chromosomal deletions and duplications that karyotyping misses. Specific gene panels may also be considered when a genetic syndrome, such as Russell-Silver syndrome or Cornelia de Lange syndrome, is suspected clinically.
Fetal Growth Restriction refers to a fetus that has not reached its biologically expected growth potential, most often due to an underlying placental, maternal, or fetal problem limiting nutrient and oxygen supply. This is different from Small for Gestational Age, which simply describes a fetus whose estimated weight falls below the tenth percentile for its gestational age, without implying that anything is pathologically wrong. Some Small for Gestational Age babies are constitutionally small and healthy, following their genetic growth potential based on parental size and ethnicity. Fetal Growth Restriction, by contrast, indicates a deviation from the fetus’s own expected growth trajectory, often accompanied by abnormal blood flow patterns on Doppler ultrasound, reduced amniotic fluid, or other signs of compromise. Distinguishing between the two matters because Fetal Growth Restriction carries a higher risk of stillbirth, birth complications, and long-term health issues, and requires closer monitoring than a constitutionally small but healthy fetus.
Delivery timing in Fetal Growth Restriction is a balance between the risks of prematurity and the risks of continuing a pregnancy where the fetus may not be receiving adequate oxygen and nutrients. Decisions are guided by the severity of growth restriction, Doppler findings, gestational age, and fetal heart rate patterns, with more severe or rapidly worsening cases often requiring earlier delivery, sometimes with corticosteroids given beforehand to support fetal lung maturity. Babies born with Fetal Growth Restriction have a higher risk of complications in the newborn period, including low blood sugar, difficulty maintaining body temperature, and, if born prematurely, the additional risks associated with prematurity itself. Over the longer term, children who experienced significant growth restriction in the womb have a somewhat higher documented risk of metabolic conditions later in life, including insulin resistance and cardiovascular disease, which is part of the broader understanding of how the intrauterine environment can influence health across the lifespan. For families, this makes both careful pregnancy monitoring and long-term pediatric follow-up an important part of care, rather than something that ends once the baby is delivered.
Establishing an accurate gestational age is the essential first step in diagnosis, ideally confirmed through an ultrasound scan performed early in the first trimester, since miscalculated dating is one of the most frequent reasons a fetus is wrongly labeled as growth restricted. Rather than depending on a single measurement, clinicians track growth over time through repeated ultrasound assessments of fetal biometry, generally spaced two to three weeks apart, to identify whether the fetus is following, falling away from, or plateauing on its expected growth curve. When estimated fetal weight drops below the tenth percentile and the growth trajectory shows a flattening pattern, this strengthens the case for a diagnosis of Fetal Growth Restriction rather than constitutional smallness. Doppler ultrasound plays a central role in evaluating fetal wellbeing, examining blood flow through the umbilical artery, the middle cerebral artery, and, when indicated, the ductus venosus, to determine how effectively oxygen and nutrients are reaching the fetus; the pattern of abnormality seen on these scans often directly informs how urgently delivery should be planned. Rounding out the surveillance approach, amniotic fluid volume is checked and fetal heart rate is monitored through non-stress tests and biophysical profile scoring. When the growth restriction appears alongside structural anomalies or raises suspicion of an underlying fetal or genetic condition, further genetic testing, such as chromosomal microarray analysis, may be advised to clarify the cause.
Yes, genetic testing can be valuable in a subset of Fetal Growth Restriction cases, particularly when growth restriction is severe, begins early in pregnancy, or is accompanied by structural anomalies detected on ultrasound. Chromosomal abnormalities such as Trisomy 18, Trisomy 13, and Triploidy are well recognized causes of early-onset, severe growth restriction, and chromosomal microarray analysis performed on amniotic fluid or chorionic villus sampling can detect these as well as smaller genetic deletions or duplications that a standard karyotype might miss. Single gene disorders and certain imprinting conditions, such as Silver-Russell syndrome, should also be considered when growth restriction is asymmetric, disproportionate, or associated with distinctive physical features after birth. Genetic testing is generally not the first step in isolated, late-onset growth restriction with a clear placental explanation, but should be discussed with the couple when the clinical picture is atypical, when there is a family history of genetic conditions, or when the couple wants clarity for future pregnancy planning. Genetic counseling before and after testing helps the couple understand what a result would and would not change about pregnancy management.
Gene therapy is an emerging field, and availability varies by condition. Some treatments are approved and accessible, while others are still in clinical trials or available only in limited centers. Your geneticist can advise on current options relevant to your specific condition.
Genetic testing technology continues to advance, but a past result for a specific gene doesn’t need to be repeated unless originally inconclusive. However, if an earlier test didn’t find an answer, newer, broader technology may be worth revisiting with your geneticist.
Yes. When parents are closely related, they are more likely to carry the same recessive gene changes, which increases the chance of a child inheriting a condition from both sides. Carrier screening is often recommended for couples in this situation.
Not necessarily. Depending on the condition and inheritance pattern, each pregnancy can carry an independent risk. A healthy first child doesn’t rule out risk for future pregnancies, especially for recessive conditions.
Yes. Rapid genetic testing is increasingly used in NICU settings for critically ill newborns to identify a genetic cause quickly, which can directly guide urgent treatment decisions.
The process involves a routine maternal blood draw after 10 weeks of gestation, with no fasting or special preparation required. Turnaround time is typically one to two weeks, and may run slightly longer for genome-wide panels given the additional sequencing depth and analysis involved. Results are reported per chromosome or condition category as low-probability or high-probability, sometimes with a “no result” or “redraw required” outcome if fetal fraction was insufficient as this occurs in a small percentage of cases and usually resolves with a repeat draw. A low-probability result is reassuring for the conditions screened but does not eliminate the need for a routine anomaly ultrasound at the appropriate gestational age, since Non-Invasive Prenatal Testing does not assess structural anatomy. A high-probability result, whether for a common trisomy or a genome-wide finding, should always be reviewed with a clinical geneticist or genetic counselor, who will contextualize the result’s positive predictive value, discuss confirmatory diagnostic testing options, and outline next steps before any further clinical decisions are made.
